MycoMed Technologies I Products to Prevent Infection

The Science to Save Lives

Detecting Infections
Before They Start

Slide background

Setting the Standard
in Prevention Medicine

Home Page 2021-12-22T16:50:00+00:00

Detection is the Key to Success

About MycoMed Technologies

MycoMed is focused on development and commercialization of products to enable early detection and prevention of fungal infections.

Much progress in medicine is accompanied by risks for infections, caused by weakening of natural defenses in the immune system. People who receive organ transplantation, cancer therapy and medications to suppress the immune system have risks for infections caused by fungi. These organisms are everywhere in our environment and infections are difficult to treat. Prevention is a key step to improving outcomes. Our first product, a urine test to detect fungal infections in the lung, is in clinical studies now.

Mycomed Technologies is located in the Johns Hopkins Fast Forward Accelerator in Baltimore, Maryland. This organization has been operating since 2014. MycoMed is a U.S. Small Business Administration-certified Women Owned Small Business (WOSB).

Company Announcements

Delivered oral presentation at the TIMM (Trends in Medical Mycology) meeting in Aberdeen, Scotland
View the Poster 
View the Oral Presentation Slides
USPTO Issued United States Patent No. 11,079,380 on August 3, 2021 in MycoMed’s Name
View the Patent Notice
NIH Awards Phase II SBIR #AI157572-01 to MycoMed for further development of MycoMEIA – Urine Diagnostic for Aspergillosis on March 5, 2021
USPTO issued united States Patent No. 10,585,098 on March 10 in MycoMed’s Name
View the Patent Notice
Cystic Fibrosis Foundation awards grant to JHU and MycoMed: “Urine Diagnostics for Aspergillus Airway Disease”
USPTO issued United States Patent No. 10,288,611 on May 14, 2019 in MycoMed’s Name
View the Patent Notice
On June 23, 2019 at ASM Microbe in San Francisco the MycoMed team gave an oral presentation titled “URINE DIAGNOSTIC TESTS FOR ASPERGILLOSIS”.
Download the Poster
The MycoMed team gave an oral presentation on Characterisation of mAb476-reactive galactofuranose-bearing Aspergillus antigens excreted in urine, presented April, 2019 at 29th European Congress of Clinical Microbiology and Infectious Diseases 2019; Amsterdam, Netherlands
Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis published in Clinical Infectious Diseases, Volume 67, Issue 11, 1 December 2018, Pages 1705–1711
Click to Read the Article
The MycoMed team gave an oral presentation on Development and evaluation of a rapid urine diagnostic test for pulmonary aspergillosis, presented April 21, 2018 at 28th European Congress of Clinical Microbiology and Infectious Diseases 2018; Madrid Spain
Hopkins and MycoMed team presents poster on Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis, presented Feb 3, 2018 at 8th Advances Against Aspergillus 2018; Lisbon Portugal
Download the Poster
MycoMed Technologies announces receipt of NIH Phase II STTR to support clinical development of urine aspergillosis diagnostic test, MycoFlow-Asp™
Hopkins team and MycoMed Technologies presents proof-of-concept data at the American Society of Microbiology (ASM) meeting in New Orleans, June 2-4
MycoMed Technologies partners with the NIH-supported AsTeC repository to test urine diagnostic assay

Sponsors and Partners

Johns Hopkins Medecine
Johns Hopkins Technology Ventures
The Maryland Innovation Initiative
National Science Foundation
National Institutes of Health